Member Info for Retireby40

*Organic growth

Organisms growth has been fantastic and reagents are recurring revenues so great we need more people for this as they’ll be generating income as soon as they come in.

We have partners and distributors who sell our products, particularly MWG products.

Although not good to see such a drop in relaxed due to the growth of the co and its prospects. What I find really upsetting is TW making money out of the drop. That p i s s e s me right off.

We have great tech and we are selling it hence the organic growth!! £3m in H2 FFS from £1m H1 and £1m FY19!!

We’ve already sold water testing to Lake Michigan and once the covid testing is complete we will quickly retrofit 3,000 units and then I imagine it will sell itself to utility cos, cruise liners etc. It’s still in testing. A little patience required. Yes the share price is crap but GB and team are delivering so unless you’re trading chill.

Agree to as regrew although IMO this will move a fair whack in 2021. As frustrating as the share price is I am here for the medium term but likely long term so minimum 12 months but likely longer as I see huge upside given the tech at MWG as well of course labskin at AI.

Blimey. Anyone here for the medium term shouldn’t worry whether we finish blue. I’d rather finish flat or red with a decent presentation with lots of encouraging content than 20% up on air.

A massive 2021 and lots of news due. Am not concerned if we finish down. Am holding these for a good while and supremely confident.

Looking back at many of the large labskin framework agreements they tend to be for around £200k a year, clearly depending on requirements it will differ some higher and some less. A base rate of £200k for 18 of the top 20 largest cosmetic cos is chicken feed but is £3.6m to us and chunky margins. I imagine the £200k base will increase as they use more and more and it’s the go-to. The market loves recurring revs and what a base.
Then there is China with new regs on animal testing coming in and of course the rest od Asia. A profitable H2 with £3m in revenues and I imagine most will recur next year sets up a massive 2021 without Covid plays. In fact the water monitoring and breathalyser are not Covid plays as will be needed without the virus. Exciting times. Well done GB and team.

He’s annoyingly.

In amazed. Working with 18 of top 20 skincare cos. Wow.

Full in registration again and it’ll put you through

Same here

Considering DVRG did some £500k in 2018, £1m in 2019, £1m in H1 2020 so £3m H2 2020 it is superb and they’re doing what they say. One assumes the combined year with MWG will be say £6.5m given most of its sales were also weighted to H2 and £1m in H1.

Anyway, am looking forward to an update at 2pm.

The ADVFN BB is more active than here. I think there is a lot of excitement and like you I wish I’d bought more!

TW is a bottom feeder and is as reliable as British Bulls so a little better than 50/50. Anyone listening to him deserves to lose money.

I look forward to Tuesday and am expecting a decent update but for me next year when we are above £50m market cap for a good while and getting on more radars is where’s it’s at. Have fewer retail holders and some decent funds and the like on board and I assume they will review the comms next year. Most important thing now is to deliver on strategy and improving investor relations and the like should come afterwards. I’d hope the DVRG IR website will be more inline with best-practice which it certainly isn’t at the moment. That’s by the by but I’m sure it’ll be on their agenda once the market cap increases.

For now let’s see out the year with a profitable H2 (£3m revenue) and a clear idea what we’ll be doing in Q1
2021 and beyond. Looking forward to Tuesday, the end of this year and especially 2021.

Am not concerned with TW and anyone who would either sell or short (if able to) on his advice should go ahead and learn the hard way.

The website says we work in artificial intelligence, clinical research, water technologies, medical device and life science.

The above is well and good and what I’m suggesting is for another time as they’ve clearly been manic with the takeover and day to day business and that’s what we wanna hear about on Tuesday, what’s going on and where the new group is headed.

I think next year is the time with the number of plates that are spinning To present a structural breakdown. Perhaps a divisional structure and breakdown would be great as we can see what each is doing financially, where (geographies), partners/collaborations etc. Yes we work on AI but that’s across a few areas as is used all over (Labskin, water-monitoring, medical device, Parity and others) and a breakdown would be good.

Would it be -

Labskin (Labskin AI)
Rinodrive
Water-monitoring (and real-time monitoring with AI)
AMBC

I’m not sure you’d have a diagnostics Division for the breathalyser so perhaps that could go into monitoring and do away with the water element.

Am not sure about desalination or Stoer and the smaller elements of the business but one for next summer or the like when there is more time!

Anyway, great to have these issues and here’s to a great end to the year.

We have Labskin/ Labskin

I’d prefer no major rise before The presentation and a decent, sustained one thereafter.

I hope the structure and content are bang on. I’m sure there is an awful lot to talk about and I agree I hope it’s well prepared and the most salient points are covered.

I think GB a superb CEO which is the most important element, creating shareholder value which is via a sustainable business model and I believe we
Are at the end of the beginning and will have a massive 2021 and beyond. Whether you think GB is the best presenter or not it’s about the content and strategy and I’m confident that will be well received by those watching. A clear roadmap with straightforward messaging to articulate what the upcoming plans are and where we are headed.

A lot of spinning plates and tricky to know how big some of the plays will be which makes it all the more exciting.

The idea has certainly generated attention among broadcasters and advertisers. Mirriad says it is already working with companies such as Tencent Video, 20th Century Fox, RTL, Channel 4 and France TV, and has previously worked with ABC to integrate brands like Pepsi and Sherwin Williams into its hit show Modern Family. Other brands it is working with include P&G, Huawei and T-Mobile.

For the moment, it seems Mirriad has the market largely to itself. Beringer says there are companies in gaming who offer a similar service, but “no companies that do what we do across linear and digital at the scale we do it.�

Indeed, the company says it has 19 patents globally covering key components of its technology, around areas such as continuity, dynamic segment insertion and content valuation.

Zig Zag has not used the platform, but started talking to Mirriad about the platform last summer. Graff says he’s never been offered a similar kind of service before.

TW is as good as BritishBulls, not far from a mug punter you meet down the pub, better than 50:50 calls but not by much. I mean some of his recent calls have been shocking but he does have a following and loyal ones which is another reason why DVRG in the next phase of growth will lovely lose some retail punters and pick up some IIs. Sure they will happen as a result of higher share price with retail profit taking and others With deeper and more patient pockets seeing the bigger picture.

TW is wrong on this one. Am glad!

'Cleaning manufactures go to labskin to test / validate there products''

These results validate Labskin's ability to provide access to real-world clones of the human skin microbiome while removing the risk of transmission of the virus to human volunteers. For the first time, in safety, clients can test their products, ingredients, treatments and therapies on SARS-CoV-2 and potentially other dangerous viruses and pathogens in real-world environments.

Add in all the other revenue stream and must be winner in the end.

Dr Cardente highlighted the Deepverge Microtox PD technology

The mechanism of detection of SARS-Cov-2 with the Microtox Optofluidic monitor

Microfluidics, Photonics and AI

Microtox PD was explained in depth in its use of AI and Machine learning; the platforms merging of microfluidics, photonics and AI; and its potential to detect a range of bad actors in water in real time. The systems history of development from an E. coli detection system developed with the Environment Protection Agency, Ireland to its application today in Covid detection was also highlighted.

As Deepverge continues to work with the scientific community across the world, it will continue listening and learning from the science and continuously work to develop surveillance systems for Covid-19 and other pathogens, viruses and bad actors that pollute the worlds water, not only detecting outbreaks, but also – and ultimately – signalling the size of a cluster to help authorities take appropriate and weighted remedial action.